You are here

Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI110048-01
Agency Tracking Number: R43AI110048
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3805 Old Easton Road
Doylestown, PA 18902-8400
United States
DUNS: 78290773
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 EMRE KOYUNCU
 (267) 893-6755
 emre@forgelifescience.com
Business Contact
 LILLIAN CHIANG
Phone: (267) 893-6755
Email: lillian@forgelifesciences.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effectiveness of 9% observed for 65+ elderly, an at-risk population for respiratory complications. Of note, the reportreinforces the need for continued advances in influenza vaccines, especially to increase protective benefits for older adults and notes, this season...antiviral treatment of elderly adults is especially important...preferably within 48 hours after illness onset... This past season's apparent mediocre protection against seasonal influenza also reemphasizes the threat of emergence of highly pathogenic pandemic strains as well as the potential use of influenza as a vehicle for biological warfare. Cur

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government